[123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study.

MLA

Oudot, Alexandra, et al. “[123I]MIBG Is a Better Early Marker of Anthracycline Cardiotoxicity than [18F]FDG: A Preclinical SPECT/CT and Simultaneous PET/MR Study.” EJNMMI Research, vol. 11, no. 1, Sept. 2021, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s13550-021-00835-1.

APA

Oudot, A., Courteau, A., Guillemin, M., Vrigneaud, J.-M., Walker, P. M., Brunotte, F., Cochet, A., & Collin, B. (2021). [123I]MIBG is a better early marker of anthracycline cardiotoxicity than [18F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study. EJNMMI Research, 11(1), 1–11. https://doi.org/10.1186/s13550-021-00835-1

Chicago

Oudot, Alexandra, Alan Courteau, Mélanie Guillemin, Jean-Marc Vrigneaud, Paul Michael Walker, François Brunotte, Alexandre Cochet, and Bertrand Collin. 2021. “[123I]MIBG Is a Better Early Marker of Anthracycline Cardiotoxicity than [18F]FDG: A Preclinical SPECT/CT and Simultaneous PET/MR Study.” EJNMMI Research 11 (1): 1–11. doi:10.1186/s13550-021-00835-1.